Long-term safety of ultevursen for retinitis pigmentosa
Part of Brain & nervous system, Ear, nose & throat, Eyes & vision, Genetic & congenital clinical trials.
This study checks the long-term safety of a medicine called ultevursen for people with retinitis pigmentosa caused by changes in a specific gene. It is for people who have already finished the earlier LUNA study and might continue treatment or just be followed for observation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have completed the LUNA study through 24 months.
- You must be at least 8 years old (minors need parent permission).
- You must be willing to attend all study visits for 24 months.
- If you are in the treatment group, you must not be pregnant or breastfeeding and must use effective birth control.
- You must not have new eye problems or allergies that make the injection unsafe.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This 24-month study tests an experimental medication, NPI-001, to see if it can slow or prevent further vision loss in people with Usher syndrome. Usher syndrome affects hearing and vision, and this trial focuses on protecting the light-sensing cells in the retina.
This study tests a new gene therapy called UGX202 for people with advanced retinitis pigmentosa, an eye disease that causes vision loss. The goal is to see if it is safe and if it can help improve vision.
This study tests a 24-month treatment with NPI-001, an oral medication, to see if it can slow the loss of light-sensing cells in the retina for people with retinitis pigmentosa tied to Usher syndrome. It aims to preserve remaining vision and delay further damage.
This trial tests a new form of the drug pitavastatin, which is usually used for cholesterol, but here it's given as tiny particles injected into the eye. The goal is to see if it's safe and might help people with retinitis pigmentosa, a condition that causes vision loss.
This trial tests an investigational gene therapy injection (UGX202) for people with advanced retinitis pigmentosa. The goal is to see if the injection is safe and can help preserve or improve vision in people who still have some memory of seeing.
This study tests a new gene therapy that may help people with advanced retinitis pigmentosa see better. It uses a modified virus to deliver a light-sensitive protein to the retina, and the trial compares the real treatment to a sham (fake) procedure to check safety and effectiveness.
Hear when a new Retinal Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.